Pancreatic cancer is a highly lethal disease, where the mortality closely matches increasing
incidence. Pancreatic ductal adenocarcinoma (PDAC) is the most common histologic type …

Background Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is
approved for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) …

Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with half of patients
diagnosed in the metastatic setting. Until recently, patients after progression on front-line …

Liposomal irinotecan (nal-IRI; Onivyde®; also known as pegylated liposomal irinotecan) has
been developed with the aim of maximising anti-tumour efficacy while minimising drug …

Introduction: Systemic chemotherapy remains the standard of care for patients with
advanced pancreatic ductal adenocarcinoma (PDAC). The introductions of FOLFIRINOX …

Objectives Liposomal irinotecan (nal-IRI) is a topoisomerase inhibitor proven to improve
survival in metastatic pancreatic cancer (mPC). This study describes real-world …

Background The efficacy of combination chemotherapy beyond the first-line setting remains
modest in patients with advanced pancreatic adenocarcinoma (PAC). Evidence from recent …

Introduction This multicenter, real-world cohort study aimed to evaluate the effectiveness of
early cumulative dose administration and dosing pattern of liposomal irinotecan plus …

Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+ 5-FU/LV) has shown to provide
survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. The majority of patients are
diagnosed with locally advanced or metastatic disease with a prognosis of short months …